Quarterly ResultMay 8, 2026, 04:08 PM
Femasys Q1 Net Income $846K; Sales +24.5%; Advances FemBloc & FemaSeed
AI Summary
Femasys Inc. reported a net income of $846,100 for Q1 2026, a significant improvement from a net loss of $5.9 million in the prior year, with sales increasing 24.5% to $424,889. The company made substantial clinical, regulatory, and commercial progress, including initiating patient enrollment in the FINALE pivotal trial for FemBloc® and receiving AMA CPT code approval for FemaSeed®. Strategic partnerships were established to expand international market access and commercialization. Femasys expects its current cash resources of $5.4 million to fund operations into Q3 2026.
Key Highlights
- Net income of $846,100 for Q1 2026, a significant turnaround from a $5.9M net loss in Q1 2025.
- Sales increased 24.5% to $424,889 in Q1 2026, primarily driven by FemBloc product sales.
- Research and development expenses decreased 55.9% to $1,309,401 in Q1 2026.
- Initiated patient enrollment in the FINALE pivotal clinical trial for FemBloc® non-surgical permanent birth control.
- Received AMA CPT Editorial Panel approval for a new Category III CPT code for FemaSeed® intratubal insemination.
- Appointed John Canning as Chief Operating Officer and Kenneth D. Eichenbaum to the Board of Directors.
- Cash and cash equivalents were approximately $5.4 million as of March 31, 2026, sufficient into Q3 2026.